ES2026304A6 - Procedimiento de fabricacion de una forma de dosificacion de nicardipina. - Google Patents

Procedimiento de fabricacion de una forma de dosificacion de nicardipina.

Info

Publication number
ES2026304A6
ES2026304A6 ES9000257A ES9000257A ES2026304A6 ES 2026304 A6 ES2026304 A6 ES 2026304A6 ES 9000257 A ES9000257 A ES 9000257A ES 9000257 A ES9000257 A ES 9000257A ES 2026304 A6 ES2026304 A6 ES 2026304A6
Authority
ES
Spain
Prior art keywords
dosage form
calcium antagonist
administering calcium
administering
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES9000257A
Other languages
English (en)
Inventor
Joseph C Deters
David R Swanson
Rosa Stephen C De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of ES2026304A6 publication Critical patent/ES2026304A6/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PROCEDIMIENTO DE FABRICACION DE UNA FORMA DE DOSIFICACION DE NICARDIPINA. COMPRENDE: MEZCAR EN SECO NICARDIPINA, OXIDO DE POLIETILENO E HIDROXIPROPILMETILCELULOSA, A/ADIR UN DILUYENTE LIQUIDO, PASAR LA MASA MOJADA A TRAVES DE UN TAMIZ, SECAR LA MEZCLA TAMIZADA, TAMIZAR LOS GRANULOS OBTENIDOS Y CARGARLOS JUNTO CON UNA COMPOSICION MOTORA OSMOTICA EN LA TOLVA DE UNA PRENSA PARA TABLETAS CON UN SISTEMA BICAPA; COMPRIMIR LAS TABLETAS PARA OBTENER NUCLEOS COMPRIMIDOS CON DOS CAPAS LOS CUALES SE REVISTEN CON UNA COMPOSICION A BASE DE ACETATO DE CELULOSA, POLIETILENGLICOL Y UN DISOLVENTE: TALADRAR EL NUCLEO REVESTIDO CON UN LASER Y SECAR LA FORMA DE DOSIFICACION ASI OBTENIDA. APLICACION EN LA ADMINISTRACION DE NICARDIPINA A UN PACIENTE QUE NECESITE TERAPIA CARDIOVASCULAR.
ES9000257A 1989-01-30 1990-01-29 Procedimiento de fabricacion de una forma de dosificacion de nicardipina. Expired - Fee Related ES2026304A6 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30370689A 1989-01-30 1989-01-30

Publications (1)

Publication Number Publication Date
ES2026304A6 true ES2026304A6 (es) 1992-04-16

Family

ID=23173326

Family Applications (2)

Application Number Title Priority Date Filing Date
ES90901388T Expired - Lifetime ES2054333T3 (es) 1989-01-30 1989-12-18 Forma de dosificacion para administrar un antagonista del calcio.
ES9000257A Expired - Fee Related ES2026304A6 (es) 1989-01-30 1990-01-29 Procedimiento de fabricacion de una forma de dosificacion de nicardipina.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES90901388T Expired - Lifetime ES2054333T3 (es) 1989-01-30 1989-12-18 Forma de dosificacion para administrar un antagonista del calcio.

Country Status (11)

Country Link
EP (1) EP0455648B1 (es)
JP (1) JPH04503058A (es)
AU (1) AU621182B2 (es)
CA (1) CA2007106A1 (es)
DK (1) DK23790A (es)
ES (2) ES2054333T3 (es)
FI (1) FI913608A0 (es)
GR (1) GR1000419B (es)
IE (1) IE61872B1 (es)
PT (1) PT92994B (es)
WO (1) WO1990008536A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ238867A (en) * 1990-07-12 1993-08-26 Alza Corp Dosage form for delayed release comprising pharmaceutically active substance and a drug-release hindering means and a second composition which imbibes fluid, expands, and ejects the active substance from the device
US5156850A (en) * 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
US5654005A (en) * 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
WO1999029297A1 (en) * 1997-12-05 1999-06-17 Alza Corporation Osmotic dosage form comprising first and second coats
JP4533531B2 (ja) 1998-04-03 2010-09-01 ビーエム リサーチ エイ／エス 制御放出組成物
EP1429744A1 (en) 2001-09-21 2004-06-23 Egalet A/S Morphine polymer release system
EP1429739A1 (en) 2001-09-21 2004-06-23 Egalet A/S Polymer release system
EP1562552A1 (en) 2002-11-08 2005-08-17 Egalet A/S Controlled release carvedilol compositions
EP1610768B1 (en) 2003-03-26 2008-07-02 Egalet A/S Matrix compositions for controlled delivery of drug substances
WO2004084868A1 (en) 2003-03-26 2004-10-07 Egalet A/S Morphine controlled release system
WO2006030402A2 (en) * 2004-09-17 2006-03-23 Ranbaxy Laboratories Limited Dual compartment osmotic delivery device
US20060165798A1 (en) * 2005-01-27 2006-07-27 Edgren David E Oral osmotic dosage form having a high flux membrane
WO2008148798A2 (en) 2007-06-04 2008-12-11 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
AU2010211220B2 (en) 2009-02-06 2013-08-01 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
WO2014006004A1 (en) 2012-07-06 2014-01-09 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4519801A (en) * 1982-07-12 1985-05-28 Alza Corporation Osmotic device with wall comprising cellulose ether and permeability enhancer
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4753802A (en) * 1986-03-19 1988-06-28 Alza Corporation Verapamil dosage form

Also Published As

Publication number Publication date
PT92994B (pt) 1995-12-29
FI913608A0 (fi) 1991-07-29
AU4811490A (en) 1990-08-24
IE900296L (en) 1990-07-30
GR1000419B (el) 1992-06-30
PT92994A (pt) 1990-07-31
IE61872B1 (en) 1994-11-30
WO1990008536A1 (en) 1990-08-09
ES2054333T3 (es) 1994-08-01
JPH04503058A (ja) 1992-06-04
DK23790A (da) 1990-07-31
EP0455648A1 (en) 1991-11-13
CA2007106A1 (en) 1990-07-30
AU621182B2 (en) 1992-03-05
GR900100015A (en) 1991-06-07
DK23790D0 (da) 1990-01-29
EP0455648B1 (en) 1993-03-10

Similar Documents

Publication Publication Date Title
GR900100659A (en) Dosage form for administering oral hupoglycemic glipizide
MX9700081A (es) Composiciones farmaceuticas de tacrina.
ES2026304A6 (es) Procedimiento de fabricacion de una forma de dosificacion de nicardipina.
WO1994027589A3 (en) Antidepressant dosage form
NZ336055A (en) An oral sustained release formulation of opioids
DK0600079T3 (da) Oral 1alpha-hydroxyprævitamin D
LTIP702A (en) A slimming pharmaceutical composition
FI925342A0 (fi) Menetelmä terapeuttisesti aktiivisen (+)- -(2,3-dimetoksifenyyli)-1-/2-(4-fluorifenyyli)etyyli/-4-piperidiinimetanolin valmistamiseksi
EP0552256A4 (es)
IL103303A (en) Pharmaceutical compositions containing ibuprofen and codeine for relief of chronic pain
MX9802150A (es) Inhibicion del factor alfa de necrosis tumoral.
HU883863D0 (en) Process for the preparation of producing and/or portionly form of therapeutical agents
NZ229518A (en) Pharmaceutical dosage form for the medication of fish: method of administration and (prophylactic) treatment
ZA898667B (en) Use of acetyl l-carnitine in the therapeutic treatment of cataract and pharmaceutical compositions useful in such treatment
UA19756A1 (uk) Спосіб одержаhhя піперазиhілалкіл-3(2h)піридазиhоhів або їх фармацевтичhо прийhятих солей
NZ225950A (en) Calcium citrate malate in the molar ratio of 6:2:3; pharmaceutical compositions
GR3025518T3 (en) Use of the N-n-butyl derivative of desoxynojirimycin in the manufacture of a medicament inhibiting HIV-Virus
NZ303993A (en) Pharmaceutical compositions containing aminotetralin derivatives for treating cardiac disorders
BG102266A (en) Method for the preparation of solid batched forms having very low doses of the medicamentous form
NO912497L (no) Doseringsform for administrering av kalsiumantagonist.
HUT73500A (en) Use of benzydamine for producing pharmaceutical compositions for treatment of pathological conditions caused by tnf
YU15301A (sh) PRIMENA R (+)- alfa-(2,3-DIMETOKSIFENIL)-1-[2-(4-FLUOROFENIL) ETIL] -4-PIPERIDINMETANOLA ZA LECENJE POREMEĆAJA SPAVANJA
TW360538B (en) Pharmaceutical composition containing 4'-iodo-4'-deoxydoxorubicin for treatment of amyloidosis

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20000403